Risk-based approach and pharmaceutical compliance in the sphere of state supervision of illegal circulation of medical products

Cover Page

Cite item

Full Text

Abstract

The article deals with the problems of introducing a risk-based approach to the regulation of federal state supervision in the sphere of circulation of medicines. The main drawbacks of the risk-based approach regulation in the regulatory legal acts of the Russian Government and Roszdravnadzor are highlighted. The discrepancy of certain provisions of the relevant acts to the principles of administrative law and the Code of the Russian Federation on administrative offences in the part relating to the assessment of the legal value of the period during which a person is considered to be subjected to administrative punishment is noted. Measures to improve the risk-based approach to the organization of state supervision in the sphere of circulation of medicines are proposed. In particular, data on the degree of compliance of the objects of control with the requirements of good practices (GxP, including GMP, GPP, GDP, etc.) and data on the presence of the objects of control systems of pharmaceutical compliance are proposed in the assessment of the risk of harm. The authors formulated the definition of the concept of pharmaceutical compliance. It is concluded that the inconsistency of the administrative-legal and criminal-legal policies to combat cartels in the EAEU member States creates significant risks to achieve the goals of creating a single market of medical products in the Eurasian Economic Union.

About the authors

Sergey V. Maksimov

ISS RAS

Author for correspondence.
Email: sergeymax2006@yandex.ru

Doctor of Law, Professor, Chief Researcher of the Institute for Study of Science of the Russian Academy of Sciences (ISS RAS), Advisor to the Head of the Federal Antimonopoly Service (FAS of Russia)

Russian Federation, Moscow

Tatyana Yu. Rudaya

Rostov Law Institute of the Ministry of Internal Affairs of the Russian Federation

Email: rydau@rambler.ru

PhD in Law, Professor of the Department of Criminal Law and Criminology

Russian Federation, Rostov

Kanat A. Utarov

South Kazakhstan state University named after M. Auezov

Email: koben_kok_koz@mail.ru

PhD in Law, Senior Lecturer of Chair of Criminal Procedure and Criminalistics

Kazakhstan, Shymkent

References

  1. Акимова И. В., Гавриленко Д. А. Антимонопольный комплаенс как инструмент повышения стоимости компании // Российское конкурентное право и экономика. 2017. № 3. С. 42-45.
  2. Гражданское право. Учебник в 2 т. / Под ред. Е. А. Суханова. М., 1998. С. 48.
  3. Комментарий к Руководству Европейского Союза по надлежащей практике производства лекарственных средств для человека и применения в ветеринарии (EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use). 2-е изд., перераб. и доп. М., 2014. С. 6-32.
  4. Контрольно-надзорная деятельность в Российской Федерации: Аналитический доклад. 2013. 2-е изд., доп. М., 2014. С. 20-21.
  5. Лисицын-Светланов А. Г., Максимов С. В. Кризис системы государственного контроля в сфере экономики и перспективы конституционного статуса контрольной ветви власти // Конституция России и отраслевое законодательство: материалы Всероссийской научно-практической конференции, посвященной 20-летию Конституции РФ. М., 2014. С. 21-22.
  6. Максимов С. В., Утаров К. А. Уголовная политика в сфере защиты конкуренции: цели и возможности / Под ред. В. П. Заварухина. М., С. 26, 29, 55, 76.
  7. Хамуков М. А., Кониева Ф. И. Руководство по выявлению и профилактике картелей на торгах. Научно-практическое пособие. М., 2019. С. 25.
  8. Чиркин В. Е. Контрольная власть. М., 2008. С. 100.
  9. Шевырёв Д. Н. Правовые основы взаимодействия органов государственной власти в сфере оборота лекарственных средств // Вестник Дальневосточного юридического института МВД России. 2017. № 3. С. 135-139.

Copyright (c) 2019 Maksimov S.V., Rudaya T.Y., Utarov K.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies